06:54 AM EST, 12/11/2024 (MT Newswires) -- Evotec (EVO) said Wednesday that LAB eN2, its translational drug discovery accelerator with Novo Nordisk ( NVO ) , has chosen its first three projects with Boston University, Harvard University, and the Joslin Diabetes Center.

Financial terms of the projects weren't disclosed.

The projects will focus on research for different cardiometabolic conditions and will be initially financed with a Discovery Award to attain select pre-clinical value-inflection points, the company added.

Evotec said LAB eN2 also intends to include Boston Children's Hospital, Boston University, Johns Hopkins University, and the Icahn School of Medicine at Mount Sinai.

The companies partnered in September last year to roll out LAB eN2, which focuses on therapeutics for cardiometabolic diseases and rare blood and endocrine disorders.